These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12648945)

  • 1. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination.
    Prinz C; Hafsi N; Voland P
    Trends Microbiol; 2003 Mar; 11(3):134-8. PubMed ID: 12648945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
    Banga Ndzouboukou JL; Lei Q; Ullah N; Zhang Y; Hao L; Fan X
    Helicobacter; 2021 Feb; 26(1):e12758. PubMed ID: 33259676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The design of vaccines against Helicobacter pylori and their development.
    Del Giudice G; Covacci A; Telford JL; Montecucco C; Rappuoli R
    Annu Rev Immunol; 2001; 19():523-63. PubMed ID: 11244046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection Against
    Pan X; Ke H; Niu X; Li S; Lv J; Pan L
    Front Immunol; 2018; 9():1003. PubMed ID: 29867978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C-terminally encoded, MHC class II-restricted T cell antigenicity of the Helicobacter pylori virulence factor CagA promotes gastric preneoplasia.
    Arnold IC; Hitzler I; Engler D; Oertli M; Agger EM; Müller A
    J Immunol; 2011 Jun; 186(11):6165-72. PubMed ID: 21518972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in vaccination against Helicobacter pylori.
    Velin D; Michetti P
    Expert Rev Gastroenterol Hepatol; 2010 Apr; 4(2):157-66. PubMed ID: 20350263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on
    Guo L; Yang H; Tang F; Yin R; Liu H; Gong X; Wei J; Zhang Y; Xu G; Liu K
    Front Cell Infect Microbiol; 2017; 7():349. PubMed ID: 28824883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model.
    Guo L; Liu K; Xu G; Li X; Tu J; Tang F; Xing Y; Xi T
    Appl Microbiol Biotechnol; 2012 Sep; 95(6):1437-44. PubMed ID: 22569640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.
    Hatzifoti C; Roussel Y; Harris AG; Wren BW; Morrow JW; Bajaj-Elliott M
    Helicobacter; 2006 Apr; 11(2):113-22. PubMed ID: 16579841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological features and efficacy of the reconstructed epitope vaccine CtUBE against Helicobacter pylori infection in BALB/c mice model.
    Guo L; Liu K; Zhao W; Li X; Li T; Tang F; Zhang R; Wu W; Xi T
    Appl Microbiol Biotechnol; 2013 Mar; 97(6):2367-78. PubMed ID: 23064457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model.
    Song H; Lv X; Yang J; Liu W; Yang H; Xi T; Xing Y
    Appl Microbiol Biotechnol; 2015 Nov; 99(22):9495-502. PubMed ID: 26062531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection.
    Keikha M; Eslami M; Yousefi B; Ghasemian A; Karbalaei M
    J Cell Physiol; 2019 Dec; 234(12):21460-21470. PubMed ID: 31188484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils.
    Guo L; Yin R; Xu G; Gong X; Chang Z; Hong D; Liu H; Ding S; Han X; Li Y; Tang F; Liu K
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28851031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice.
    Li X; Xing Y; Guo L; Lv X; Song H; Xi T
    Pathog Dis; 2014 Oct; 72(1):78-86. PubMed ID: 24687988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental model of Helicobacter pylori infection.
    Del Giudice G; Ghiara P; Rappuoli R
    Ital J Gastroenterol Hepatol; 1998 Oct; 30 Suppl 3():S261-3. PubMed ID: 10077750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation.
    Prinz C; Schöniger M; Rad R; Becker I; Keiditsch E; Wagenpfeil S; Classen M; Rösch T; Schepp W; Gerhard M
    Cancer Res; 2001 Mar; 61(5):1903-9. PubMed ID: 11280745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A vaccine against Helicobacter pylori infection].
    Presecki V; Katicić M; Kalenić S; Strnad M; Plecko V; Babus V; Dominis M
    Lijec Vjesn; 2002 Sep; 124 Suppl 1():79-82. PubMed ID: 12592824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice.
    Li HB; Zhang JY; He YF; Chen L; Li B; Liu KY; Yang WC; Zhao Z; Zou QM; Wu C
    Vaccine; 2012 Dec; 31(1):120-6. PubMed ID: 23137845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulated regulatory T cell function is associated with increased peptic ulcer in Helicobacter pylori-infection.
    Bagheri N; Shirzad H; Elahi S; Azadegan-Dehkordi F; Rahimian G; Shafigh M; Rashidii R; Sarafnejad A; Rafieian-Kopaei M; Faridani R; Tahmasbi K; Kheiri S; Razavi A
    Microb Pathog; 2017 Sep; 110():165-175. PubMed ID: 28666843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.
    Malfertheiner P; Selgrad M; Wex T; Romi B; Borgogni E; Spensieri F; Zedda L; Ruggiero P; Pancotto L; Censini S; Palla E; Kanesa-Thasan N; Scharschmidt B; Rappuoli R; Graham DY; Schiavetti F; Del Giudice G
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):698-707. PubMed ID: 30042064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.